Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy
作者: Usman BaberM. Urooj ZafarGeorge DangasGinés EscolarDominick J. AngiolilloSamin K. SharmaAnnapoorna S. KiniSamantha SartoriLauren JoyceBirgit VogelSerdar FarhanPaul GurbelC. Michael GibsonValentin FusterRoxana MehranJuan J. Badimon
作者单位: 1Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
2Atherothrombosis Research Unit, Icahn School of Medicine at Mount Sinai, New York, New York
3Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida
4Inova Center for Thrombosis Research and Translational Medicine, Falls Church, Virginia
5Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical, Harvard Medical School, Boston, Massachusetts
刊名: Journal of the American College of Cardiology, 2020, Vol.75 (6), pp.578-586
来源数据库: Elsevier Journal
DOI: 10.1016/j.jacc.2019.11.056
关键词: Blood thrombogenicityPlatelet aggregationTicagrelor
英文摘要: Abstract(#br)Background(#br)An evolving strategy in the setting of percutaneous coronary intervention (PCI) involves withdrawal of acetylsalicylic acid (ASA), or aspirin, while maintaining P2Y 12 inhibition. However, the pharmacodynamic effects of this approach on blood thrombogenicity and platelet reactivity remain unknown.(#br)Objectives(#br)This study sought to compare the antithrombotic potency of ticagrelor alone versus ticagrelor plus ASA among high-risk patients undergoing PCI with drug-eluting stents.(#br)Methods(#br)This was a mechanistic substudy within the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention) trial, which randomized patients undergoing PCI to ticagrelor plus placebo versus ticagrelor plus ASA following 3 months of dual...
全文获取路径: Elsevier  (合作)
影响因子:14.086 (2012)

  • PCI Peripheral Component Interconnection